EUNew treatments and approvals
EU approves a gene therapy gel applied to wounds in dystrophic butterfly skin disease
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The European Commission approved beremagene geperpavec for wounds in dystrophic butterfly skin disease (dystrophic epidermolysis bullosa). The drug can be used from birth in patients with a change in the COL7A1 gene. The gel is applied to the wound once a week. The main study included 31 patients aged 1 to 44 years. After six months, 67% of wounds treated with the gel had healed completely, compared with 22% with a placebo gel.
What does it mean for patients and families?
The treatment targets the wounds, not the disease itself. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Epidermolysis bullosa (butterfly skin disease)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.